Treatment | Number of ulcers during treatment | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patient no. | Activity score | Systemic sclerosis (SSc) type | DD (years) | Age (years) | Previous and concomitant | Start | Duration (months) | Dosage (mean, mg/day) | Start | Min | End | Compl heal | New | Side effects |
1 | 4.5 | Diff | 2 | 69 | CCB, PC (4), PX | January | 2§ | 50 | 1 | 0 | 0 | 1 | 0 | No |
2 | 2.0 | Lim | 41 | 51 | SL, CCB, PC (2), ASA | October | 1‡ | 150 | 1 | 1 | 1 | 0 | 0 | No |
3 | 3 | Lim | 0.5 | 40 | PC (3.5), CCB, SL, P (7.5) | September | 3§ | 150 | 3 | 1 | 2 | 2 | 1 | No |
4 | 3.0 | Diff | 25 | 54 | ACE, CCB, ASS, P (2.5) | February | 6 | 50 | 1 | 0 | 0 | 1 | 0 | No |
5 | 2.5 | Lim | 11 | 59 | PX, PC (3), CCB, HQ, P (4), | February | 6 | 150 | 1 | 0 | 0 | 1 | 0 | E, Fl, Pa, Dizz, Rx |
6* | 0.5 | Diff | 5 | 55 | PC (1.5), SG, CCB, AB, ACE | April | 2.5† | 75 | 2 | 0 | 0 | 2 | 0 | Dys, E, WI |
7 | 1.0 | Lim | 0.5 | 39 | PC (5), CCB, ATB, P (7) | January | 6 | 100 | 3 | 0 | 0 | 4 | 1 | Fl, Pa, RRR, Rx |
8 | 5.0 | Diff | 5 | 58 | AA, CCB, ACE, PC (4) | October | 6 | 150 | 2 | 0 | 1 | 2 | 1 | Fl |
9 | 1.0 | Lim | 3 | 29 | CCB, PX, ASA, | January | 6 | 150 | 2 | 1 | 1 | 1 | 0 | E |
10* | 1.0 | Lim | 6 | 70 | PC (4), SG, CCB, ACE AZA, P (5), PX | August | <1† | 50 | 5 | 5 | 5 | 0 | 0 | AF, Dizz |
11 | 1.0 | Lim | 6 | 48 | PP, PC (2), PX, CCB, AC | May | <1‡ | 75 | 2 | 2 | 2 | 0 | 0 | No |
12 | 2.5 | Diff | 2 | 54 | CCB, ACE, PC (2.5), AB, ATB | May | 6 | 125 | 5 | 0 | 2 | 5 | 2 | RRR |
13 | 2.0 | Diff | 11 | 43 | PC (6), CCB, PX, P (5) | August | 6 | 50 | 2 | 0 | 3 | 2 | 3 | E, Fl, Pa, MP |
14 | 1.0 | Diff | 7 | 43 | PC (3), CCB, ASA, P (5) | April | 6 | 75 | 4 | 1 | 2 | 3 | 1 | WI, Pa, RRR |
15 | 2.0 | Lim | 9 | 60 | SG, PC (3), CCB, ACE | January | 6 | 150 | 6 | 2 | 2 | 5 | 1 | No |
16 | 2.5 | Diff | 22 | 51 | SG, PC (3), PX, ASA | February | 4§ | 150 | 4 | 2 | 2 | 3 | 1 | No |
17 | 3.0 | Diff | 17 | 65 | PC (2), PX, CCB, CYC, P (10) | May | 6 | 100 | 6 | 2 | 2 | 5 | 1 | No |
18 | 1.5 | Lim | 14 | 38 | SG, PC (5), CCB, PX, PP, P (7.5) | March | 6 | 150 | 5 | 0 | 0 | 5 | 0 | No |
19 | 2.0 | Lim | 1 | 42 | CYC, CCB, PC (2), AC | June | 6 | 150 | 2 | 0 | 0 | 2 | 0 | No |
SSc type: lim, limited; diff, diffuse.
↵* Indicates male patients.
↵† Indicates cessation of treatment due to side effects.
↵‡ Indicates cessation of treatment due to other events with possible impact on the effect of treatment (ulcer infection, cyclophosphamide use).
↵§ Indicates patients with development of new digital ulcer or calcinosis and no significant improvement by treatment.
AA, autoamputation; AB, α blocker; AC, anticoagulation; ACE, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ASA, acetyl salicylic acid; ATB, angiotensin receptor blocker; AZA, azathioprine; BWI, body weight increase; CCB, calcium channel blockers; compl heal, number of ulcers completely healed; CYC, cyclophosphamide; DD, disease duration; Dizz, dizziness; Dys, dyspnoea; E, Oedema; Fl, flush; HQ, hydroxycloroquine; MP, muscle pain; P, prednisone (mg/day); Pa, palpitations; PC, intravenous prostacyclin (weeks with maximally tolerated dose for 6 h/day); PP, plasmaphereses; PX, pentoxyphylline; RRR, reduction of RR (arterial hypertension) medication; Rx, reflux; SG, surgery; SL, sympathicolysis.